At a glance
A GHRH-related peptide studied in endocrine signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited context includes pediatric endocrine studies and other research. Results from growth hormone deficiency cannot establish a general adult anti-aging effect.[1][2][1]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Sermorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (µg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 µg | 12 units (0.12 mL) |
| Weeks 3–4 | 300 µg | 18 units (0.18 mL) |
| Weeks 5–6 | 400 µg | 24 units (0.24 mL) |
| Weeks 7–8 | 500 µg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously at bedtime. Bedtime administration is strongly recommended because endogenous GH secretion peaks during sleep[1]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily nightly regimen.
- Goal: Stimulate endogenous pituitary GH release to support physiologic IGF‑1 levels and anabolic processes[1][2].
- Schedule: Daily subcutaneous injections at bedtime for 3–6 months (pediatric trials ran 6–12 months; adult use is off‑label)[1].
- Dose Range: 200–500 µg daily (adult research range; pediatric: 30 µg/kg nightly)[1][2].
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated; reconstituted refrigerated and used within 10–14 days[3].
Suggested nightly titration approach for adult off‑label use.
- Start: 200 µg nightly at bedtime; increase by ~100 µg every 1–2 weeks as tolerated.
- Target: 300–500 µg nightly by Weeks 5–8 (adjust based on IGF‑1 response).
- Frequency: Once per day (subcutaneous, preferably before sleep)[1].
- Cycle Length: 3–6 months typical for adult research use; pediatric trials ran 6–12 months[1].
- Timing: Bedtime administration leverages natural nocturnal GH pulse; rotate injection sites systematically[5].
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously)[2].
- Label with reconstitution date and refrigerate at 2–8 °C (36–46 °F), protected from light[2][3].
- Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection[2].
Storage Instructions
Proper storage preserves peptide potency and sterility.
- Lyophilized: Store at 2–8 °C (36–46 °F) in dry, dark conditions[2]. Do not freeze dry powder; check expiration date.
- Reconstituted: Refrigerate at 2–8 °C (36–46 °F)[3]; do not freeze mixed solution[3]. Use within 10–14 days when using bacteriostatic water (multi‑dose vial).
- Allow vials to reach room temperature before reconstituting to aid dissolution; inspect solution before each use (should be clear and colorless)[2].
- Always use aseptic technique: swab stopper with alcohol before each draw; use new sterile needle and syringe per injection[2].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–week daily protocol with gradual titration (56 injections total).
-
Peptide Vials (Sermorelin, 5 mg each):
- 8 weeks (total ~19.6 mg consumed): 4 vials (20 mg total)
- 12 weeks (similar daily range): 6–7 vials
- Tip: Have 1 extra vial as backup in case of spillage or loss.
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes (recommend 1 × 100‑count box)
- 12 weeks: 84 syringes (1 × 100‑count box)
- Preferred: 0.3–0.5 mL size with 28G–31G needle, 5/16″ to 1/2″ length for subcutaneous use.
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- Contains benzyl alcohol preservative; do not use if allergic.
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- Sharps Container: One puncture‑proof disposal container for used needles (sufficient for 56+ syringes).
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
Public health resource
NCBI Bookshelf — Best practices for parenteral injections: aseptic technique, preparation, administration guidelines (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.